contact us krjpencn

회사 소개

Executive Team

현재 위치: > Executive Team

  • Chunlin Chen, Ph.D. CEO

    Chunlin Chen, Ph.D. , Founder/CEO

    Dr. Chen was founder and CEO of Medicilon Inc. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.
    In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University and an Excellent returnee award from Chinese government.

  • Shuangqing Peng Ph.D.  CSO

    Shuangqing Peng, Ph.D. , Chief Scientific Officer

    Dr. Peng is the PhD in pharmacology at Academy of Military Medical Sciences (AMMS), postdoctoral fellow in public health at Peking University and postdoctoral fellow in pharmacology at Michigan State University. Dr. Peng is also a professor and doctoral advisor of AMMS, vice president of the CSOT. He has been engaged in pre-clinical research of new drug innovation for more than 30 years, and has undertaken the construction of national GLP technology platform. Dr. Peng presided over and undertook more than 40 national scientific research projects, including 973 Project, 863 Plan and the national “New Drug Development and Innovation” Project. He has published more than 300 scientific research papers and edited 13 monographs. Dr. Peng won 12 scientific and technological achievement awards. He has received the special government allowance of the State Council, the honorary title of “National Outstanding Scientific and Technological Worker” by the China Association for Science and Technology, and the Outstanding Contribution Award of Chinese Toxicology. Dr. Peng has trained more than 90 master, doctoral and postdoctoral students. He holds academic positions such as new drug review experts and medical device review experts of NMPA, new chemical substance review experts of the Ministry of Ecology and Environment, and ETAP deputy editor-in-chief.

  • Jinna Cai, Ph.D. CBO

    Jinna Cai, Ph.D. , CBO

    Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.
    Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th –five-year “by Jiangxi Province. Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.

  • Liu Jian,Ph.D.,President of Drug Discovery Division

    Liu Jian,Ph.D.,President of Drug Discovery Division

    Dr. Liu Jian holds a Bachelor's degree in Chemistry from Peking University, a Master’s degree in Chemical Engineering from Tsinghua University, and a Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA). He subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania. In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA. In 2019, he was awarded the "Outstanding 50 Asian American in Business " by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New Jersey in 2019.
    With over 20 years of experience in the field of innovative drug development, Dr. Liu Jian has made significant contributions. Under his leadership, the team has invented and submitted10 preclinical candidates (PCCs), which have entered Phase I, II, and III clinical trials. He has filed over 72 patent applications, with 21 patents already granted. Dr. Liu Jian also possesses profound academic achievements, having published a total of 47 articles in international academic journals and serving as a reviewer for several international academic journals.
    Dr. Liu joined the industry in 2001 and has worked for Merck for nearly 20 years. He has been primarily involved and leading the R&D of novel small molecule drugs for various diseases, including osteoporosis, obesity, diabetes, cardiovascular disease, cancer, immune disease, antiviral and antibacterial and pain. He started as a Senior Research Chemist and worked his way to the Principal Scientist and External Discovery Chemistry Lead, earning the "Merck Excellence Award" four times. He later served as CSO and Operations Director at Jiangsu Hengrui Pharmaceutical USA Drug Discovery Center (EBI), where he led the development of new drugs for cancer, immune diseases, osteoarthritis, and neurodegenerative diseases. Recently, he became the CEO of Silexon AI, responsible for building the company's artificial intelligence platform and empowering innovative drug research.

  • Haizhou Zhang Ph.D.

    Haizhou Zhang,Ph.D.,President of Preclinical R&D Unit

    Dr. Zhang Haizhou holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs. Prior to joining Medicilon, Dr. Zhang had working experience in health authorities, multinational pharmaceutical companies, and CROs. As a seasoned executive and experienced R&D leader, he also has hands-on experience of preparing R&D and BD strategy, regulatory documents such as IND/CTA, NDA/MAA etc. and experience of building R&D teams, operation/compliance systems and initiating and managing collaborations with key business partners.

    As an expert in pharmaceutical R&D, Dr. Zhang Haizhou also served in various international organizations. He was a review expert of National Key Innovative Drug R&D Projects of the Ministry of Science and Technology, and also served as an invited guideline reviewer of NMPA and has participated in drafting and reviewing >10 guidelines including the guideline on biosimilars issued in Feb. 2015. He is the Vice Chair of Chinese Society of Quality Assurance in Toxicological Research, a committee member of Drug Safety Evaluation and Research Committee, Chinese Pharmaceutical Association and Drug Toxicology and Safety Evaluation Committee, Chinese Society of Pharmacology. In addition, Dr. Zhang was the founding group leader of the RDPAC Preclinical Focus Group, a former member of board of directors of Chinese Society of Toxicology and Genetic Toxicology Association (USA), etc.

  • Xingquan Ma, Ph.D. SVP of Chemistry

    Xingquan Ma, Ph.D., SVP of Chemistry

    Dr. Ma was awarded his Ph.D. degree in Bioorganic Chemistry from the prestigious Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Science in 2001. Dr. Ma was further trained over 5 years in Medical Research in top academia organizations in the United stated, such as, as Associate Researcher in the Scripps Research Institute (TSRI) with Prof. M. G. Finn, and as Postdoctoral Research Fellow at the National Institutes of Health (NIH) with Dr. Pavol Kovac.
    Dr. Ma joined Shanghai ChemPartner, an internationally famous CRO company, as Senior Director in 2006, and joined Shanghai Medicilon as VP of Chemistry in 2008. During this period of 13 years’ CRO research, Dr. Ma significantly contributed to multitudinous drug discover projects, in which currently five compounds were in clinical research stage, and one approved to market by FDA. Dr. Ma has rich experience in carbohydrate chemistry and bio-chemistry, and their related areas. Dr. Ma has over 20 peer-reviewed publications.

  • Yongmei Xu Ph.D. R&D VP of Chemistry

    Yongmei Xu ,Ph.D. , R&D VP of Chemistry

    Dr. Yongmei Xu, Ph.D. from Shanghai Organic Chemistry Institute of China Academy of Sciences, postdoctoral fellow at Stockholm University, Sweden, under the tutelage of Professor Bäckvall, Academician of the Royal Swedish Academy of Sciences. With more than 20 years of experience in drug discovery R&D, published 19 papers on internationally renowned academic journals such as Angew. Chem. Int. Ed., J. Org. Chem. and Chem. Commun.. Honored with the Tier 1 Shanghai Science and Technology Award in 2013. Since her service in Medicilon, Dr. Xu has been committed to drug discovery and led many projects of innovative pharmaceutical R&D such as anti-tumor medicine, the treatment of digestive tract diseases and diabetes, and has achieved remarkable results in the field of drug discovery.

  • Zhigang Li Ph.D. R&D VP of Chemistry

    Zhigang Li, Ph.D. , R&D VP of Chemistry

    Dr. Zhigang Li, Ph.D. in Applied Chemistry from Dalian University of Technology. Deeply engaged in research work in the State Key Laboratory of Applied Chemistry, published several papers in renowned academic journals such as Bioorg. Med. Chem., Tetrahedron. Won Shanghai Science and Technology Development Funds (B) in 2011. Applied about 20 patents in China, the United States, the European Union and the World Intellectual Property Organization. He is currently the Scientific research Vice President of Medicilon’s chemistry department. Responsible for medicinal chemistry, synthetic chemistry and other chemistry projects in drug discovery phase. Accumulated many experiences in synthesis of heterocycles, nucleosides and carbohydrates. Has worked with many domestic and foreign pharmaceutical companies and helped to advance these projects from lead optimization to pre-clinic candidate confirmation. Among them, the anti –tumor candidate PRT543 based on PRMT5 has entered phase I clinic trial in US; the second brain penetration BRAF inhibitor ABM-1310 also entered phase I clinic trial in US.

  • Baohong Cao Ph.D. VP of Pharmacology

    Baohong Cao, Ph.D. , VP of Pharmacology

    Over twenty-five years of combined professional experience in Academic research and Pharmaceutical industry and over 10 years of people/team manage experience. Surgery Ph.D. in Beijing Medical University, post-doctoral research associate at State Serum Institute, Copenhagen, Denmark. Dr. Cao used to do research work at University of Pittsburgh & Children’s Hospital of Pittsburgh, Benaroya Research Institute (Seattle) and Novartis Institutes of Biomedical Research. His work was published by top academic magazines, such as Nature Cell Biology, Nature Biotechnology and Journal of Cell Biology. Prior to Medicilon, Dr. Cao worked for Shanghai ChemPartner Co., Ltd. as senior director, MI Bioresearch Inc. as study operations director and Wuxi Apptech Inc. as senior director in Immune oncology.

  • Xiancheng Zeng Ph.D. VP of Preclinical Toxicology Research

    Xiancheng Zeng, Ph.D. , VP of Preclinical Toxicology Research

    Dr. Xiancheng Zeng, senior engineer, MD from Shanghai Institute of Pharmaceutical Industry. In 2010-2013, he served in National Research Center of Drug Safety Evaluation, during which time he was sent to CFDA to get trained and practiced on NDA. In 2013, he joined Medicilon. He now is the vice president for Toxicity Research Dept., leading the research on the toxicity study of biotechnology drugs, vaccines and chemical drugs, as well as managing the whole research department. He has participated in and led the study of general toxicity and DMPK of the research and filing of 20 chemical drugs, 8 ADC, 10 monoclonal antibodies, 2 HCGs, 2 preventive vaccines and 1 compound medicine. In addition, he served as the project manager in 2 special studies of laboratory animals that were sponsored by Shanghai Committee of Science and one “Eleven-Five” prioritized special study.

  • Wenxin Dong, Ph.D. , Vice President of Pharmacodynamics

    Dr. Dong studied at the Université Paris VI in Paris and the Académie Nationale de Médecine in France, and obtained the master and a doctorate degree in pharmacology. Dr. Dong used to be a researcher and doctoral advisor of Shanghai Institute of Pharmaceutical Industry, Director of Shanghai Pharmaceutical Association, a Deputy Director of Shanghai Pharmacology Professional Committee, member of the Society of Neuroscience and a recipient of special allowances from the State Council.

    Dr. Dong has more than 20 years of experience in preclinical pharmacological and pharmacodynamic research and new drug research and development, involving neuropsychiatry, cardiovascular and cerebrovascular diseases. She has also undertaken a number of national and municipal major new drug innovation projects and presided over the establishment of a leading technology platform for the R&D of new pharmacological and pharmacological effects of antidepressant and anti-senile dementia drugs. Dr. Dong joined Medicilon in 2017 and established nearly 200 non-tumor drug efficacy evaluation models; presided over the evaluation of more than 20 first-class innovative drugs; and led the completion of hundreds of new drug efficacy evaluations of various types at different stages.

  • Jing Deng, Ph.D. , VP of Pharmacology, Pharmacodynamics and Biology Dept.

    Jing Deng, Ph.D. , VP of Pharmacology, Pharmacodynamics and Biology Dept.

    Dr. Jing Deng obtained her Ph.D. degree from McGill University in the Department of Pharmacology and Therapeutics, and completed a postdoctoral program at Harvard Medical School. She is a member of leading biomedical research societies, including Society of Functional Precision Medicine (SFPM), American Society of Hematology (ASH), American Association of Cancer Research (AACR), and American Chinese Medical Association (ACMA). She is also recognized by a number of leadership awards, including Jiangsu Innovation and Entrepreneurship Award, and Suzhou Innovation and Entrepreneurship Award.

    In her over twenty years’ career in biomedical science, Dr. Deng has been instrumental in applying principles of molecular pharmacology, functional genomics and proteomics in translational medicine research. Some of her achievements include : 1) as a key contributor for the translational biomarker development during the collaborative projects between Dana-Farber Cancer Institute and AbbVie for the phase 1 and 2 study of the first-in-class BCL-2 selective inhibitor (venetoclax, ABT-199); 2) providing the first evidence in the world , from the mitochondrial level, that BTK inhibitors (ibrutinib and acalabrutinib) can enhance the anti-leukemic activity of BCL-2 antagonist venetoclax, which is the rationale underlying the current Gold Standard combination therapy for CLL ; 3) development of the BH3 profiling technology for better predicting patient response in cancer therapy. In the past few years, Dr. Deng has presented more than 10 significant drug discovery projects in world conferences; and published several high impact research articles in the field.

  • Jingxuan Zhang, Ph.D. , Vice President of the Preclinical Toxicology Research

    Jingxuan Zhang, Ph.D. , Vice President of the Preclinical Toxicology Research

    Dr. Jingxuan Zhang is the Doctor of Veterinary Medicine in Preventive Veterinary Medicine of China Agricultural University, master of Pharmacology and Toxicology of Shanghai Pharmaceutical Industry Research Institute - National Shanghai New Drug Safety Evaluation Research Center, bachelor of Clinical Medicine of Tongji University School of Medicine in Shanghai. Dr. Zhang is also the new drug review expert of CDE (Center for Drug Evaluation, NMPA), Chinese certified toxicologist, Chinese veterinary pathologist, member of the Toxicological Pathology Professional Committee of the Chinese Pharmaceutical Association and Chinese Society of Toxicology, director of the Veterinary Pathology of the Chinese Society of Animal Science and Veterinary Medicine, executive director of Drug Clinical Evaluation of China Medical Association of Minorities and director of the Women and Pediatric Immunology of the China Healthy Birth Science Association.

    Dr. Zhang has a solid industry foundation, research skills and outstanding leadership in the pharmaceutical industry, especially in the fields of drug toxicology, preclinical safety evaluation, and clinical medicine. Dr. Zhang has 13 years of study and work experience in the preclinical safety evaluation of new drugs in the GLP centers. She is familiar with and understands the preclinical safety evaluation processes and operations, as well as the operation management of the GLP laboratory. In addition, Dr. Zhang also has 10 years of working experience as a full-time professional leader of toxicological pathology and study director of drug toxicology in GLP centers. She is proficient in the implementation and operation management of toxicology tests, with rich experience in diagnosis of toxicological pathology/experimental animal pathology and laboratory management. Dr. Zhang completed more than 200 studies of pathological diagnosis and presided over 2 carcinogenicity studies. Furthermore, she has experience for nearly 6 years in full-time pharmacologic pathological diagnosis and traditional Chinese medicine toxicology research, and for 4 years in clinical diagnosis and treatment. In 2010, Dr. Zhang Jingxuan has passed the examinations and were qualified as chinese certified Toxicologist and chinese veterinary pathologist from the Chinese Society of Toxicology and the Chinese Society of Animal Science and Veterinary Medicine respectively. Moreover, Dr. Zhang has high academic attainments and participated in a number of scientific research projects of the National Natural Science Foundation of China, the National Science and Technology Major Project and the National Key R&D Program of China. She has published many papers and participated in the editing and publication of many academic works.

  • Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.

    Renzong Xie, Ph.D. DABT , Vice President of Toxicology Research Department

    Dr. Renzong Xie, Ph.D. in Pharmacology and Toxicology, University of Mississippi Medical Center, USA, Certified Toxicologist of the American Board of Toxicology, former member of the Drug Development Program Review Committee of the National Science and Technology Council of Taiwan, China, Ministry of Science and Technology and Ministry of Economic Affairs and the Professor of Taipei Medical University and Biotech Industrial Academy.

    Dr. Xie has been rooted in the pharmaceutical industry for more than 30 years, including 12 years of working experience in CDE in Taiwan, China. Dr. Xie was responsible for reviewing the pharmacological and toxicological test reports of IND and NDA applications, writing assessment reports and conducting risk assessments. He reviewed more than 200 IND cases, including 70 biologics drugs and more than 150 NDA cases, of which about 40 biologics drugs. He has also drafted the guidelines for non-clinical safety studies of Taiwan CDE, China, ICH S9 and E14/S7B, and several guidelines for non-clinical safety studies of Taiwan, China. In addition, Dr. Xie is also experienced in pharmacology and toxicology research, establishment of disease animal models, and the whole process of new drug development. These experiences will further promote the development of Medicilon toxicology research and improve the quality, efficiency and successful rate of project submissions.

    Before joining Medicilon, Dr. Xie served as a senior executive in Jiangxi Changpharma Inc., LongBio Pharma, and Oneness Biotech, and has excellent experience in new drug R&D and team management.

  • Christopher Stewart, DABT Ph.D. , Senior Scientific Advisor

    Christopher Stewart, Ph.D. DABT , Senior Scientific Advisor

    Dr. Christopher Stewart, Postdoctoral Fellow in Toxicology, University of Arkansas School of Medicine; fellow of the American College of Toxicology and fellow of the Society of Toxicology, with over 30 years of professional experience. Dr. Stewart is currently the Principal Consultant of SGI Consulting. He has worked in research management for MPI Research, the world's largest preclinical CRO, Charles River Laboratories, Arkansas Children's Hospital, and the US FDA.

    He has extensive practice and deep insights into GLP regulations (including FDA, EPA, OECD and JMHLW) and ICH, and has made great achievements in the field of biomedical development. Dr. Stewart also participated in the preparation of more than 300 global application filing documents, and made positive contributions to the registration of chemical drugs and biological preparations, and the development of new drugs.